Latest Metered-dose inhaler Stories
MADISON, Wis., July 11, 2012 /PRNewswire-iReach/ -- Asthmapolis announced today that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance to market its asthma sensor system and associated software to healthcare providers and their patients. (Photo: http://photos.prnewswire.com/prnh/20120711/CG38057) "We are thrilled to have achieved this important milestone to support our mission of providing tools to help patients and their healthcare providers better...
REDWOOD CITY, Calif., May 21, 2012 /PRNewswire/ -- Pearl Therapeutics Inc. has been named a TiE50 Winner. The TiE50 award was presented in Santa Clara, CA at TiEcon 2012, an annual convention hosted by The Indus Entrepreneurs (TiE), an organization dedicated to fostering entrepreneurs. The TiE50 awards program recognizes the top technology startups from the following segments: internet, energy, wireless/mobile, software and life sciences. Pearl's award was made in the life sciences...
SAN DIEGO, May 16, 2012 /PRNewswire/ -- Elevation Pharmaceuticals, Inc., a pharmaceutical company focused on the development of new aerosol therapies for patients with respiratory diseases, announced today positive results from a Phase 2b study of EP-101 in patients with chronic obstructive pulmonary disease (COPD), a progressive disease comprising chronic bronchitis and emphysema caused largely by smoking. Patients with moderate to severe COPD treated with EP-101 after seven days...
In the news release, Pearl Therapeutics Phase 2b Twice-Daily Dosing Data Suggest Morning and Evening Benefit of PT003 in Patients with COPD, issued 14-May-2012 by Pearl Therapeutics over PR Newswire, we are advised by the company that the dateline date should read "May 14, 2012" rather than "May 14, 2011" as originally issued inadvertently. The complete, corrected release follows: Pearl Therapeutics Phase 2b Twice-Daily Dosing Data Suggest Morning and Evening Benefit of PT003 in Patients...
REDWOOD CITY, Calif., May 14, 2011 /PRNewswire/ -- Pearl Therapeutics Inc. announced plans to make 11 presentations at upcoming medical meetings to report clinical and product development information pertaining to PT003 (GFF MDI), a proprietary, fixed-dose combination of glycopyrrolate (GP), a long-acting muscarinic antagonist (LAMA) and formoterol fumarate (FF), a long-acting beta-2 agonist (LABA). PT003 and its components, PT001 (GP MDI) and PT005 (FF MDI) are being developed...
Asthmatics Can Save Money Safely by Buying from VIPPS Certified Online Pharmacies Partnership for Safe Medicines WASHINGTON, May 2, 2012 /PRNewswire-USNewswire/ -- Asthmatics suffer from both chronic shortness of breath that if treated inconsistently can lead to serious illness and the burden of daily medication which requires conscientious treatment as well as expense. With this double burden, asthmatics may wonder if there is a reasonable...
ALBANY, New York, April 30, 2012 /PRNewswire/ -- 35 Premium Reports Available on Catheters Market Covering Central Venous Catheters, Diagnostic Electrophysiology Catheters, Electrophysiology (EP) Ablation Catheters, Cardiac Catheters, Peripheral Intravenous Catheters and other catheters reports. Browse all Catheters Market [http://www.researchmoz.com/catheters-market.htm ] Research Reports & Catheters Industry Analysis...
MUMBAI, India, April 10, 2012 /PRNewswire/ -- SPARC Ltd's Combitide Starhaler(R) for asthma and COPD is a finalist at the 2012 Medical Design Excellence Awards (MDEA) to be held in Philadelphia this May. MDEA is the premier awards program for the medical technology community, and the only awards program that exclusively recognizes contributions and advances in the design of medical products. Combitide Starhaler(R) is a novel, high performance multi dose dry...
Under Economic Strain, More Women Rely on Community Health Centers for their Daily Health Needs SANTA BARBARA, Calif., April 3, 2012 /PRNewswire-USNewswire/ -- In an effort to provide better care to uninsured women across the country, Teva Pharmaceuticals has provided Direct Relief USA with a donation of women's health products valued at $3 million (wholesale). The donation of 5,000 units of ParaGard®, an intrauterine copper contraceptive, will be distributed by Direct Relief to the...
REDWOOD CITY, Calif., April 3, 2012 /PRNewswire/ -- Pearl Therapeutics Inc. today announced that the company has successfully formulated and manufactured metered-dose inhalers (MDI) that deliver 300ng per actuation of glycopyrrolate (GP), a highly potent, long-acting muscarinic antagonist (LAMA) using its porous particle cosuspension technology. By breaking the microgram dose barrier, Pearl aims to evaluate completely the safety and efficacy profiles of GP, and other very potent...
Latest Metered-dose inhaler Reference Libraries
Nicotine replacement therapy is the administration of nicotine by other means than smoking. This change in the way nicotine is delivered prevents the harmful effects of smoking and is usually used in smoking cessation. Types Nicotine replacement therapy can be administered in several forms. The type used depends on the patient and what fits into their lifestyle best. The forms available include: Nicotine patches – transdermal (through the skin) Nicotine gum – orally (through the...
